In 2025, an independent team led by St Mary's University, Twickenham, published a double-blind, randomised, placebo-controlled trial on our liposomal turmeric in the peer-reviewed journal Physiological Reports.
The study's starting point is the same reason we make curcumin the way we do: ordinary curcumin is notoriously poorly absorbed. It's water-insoluble and poorly taken up in the gut, which means much of a standard dose is never used. Our liposomal (hydrolysed) form was developed to overcome exactly that, improving curcumin's solubility and raising the amount that reaches the bloodstream.
Over seven days, at one and two sachets a day, the trial measured markers of muscle damage, inflammation, oxidative stress, perceived soreness and muscle performance during recovery from intense exercise.
There are currently no authorised health claims for curcumin in GB, so we're not able to describe its health effects or state what the study found on this page. The full results are published and freely available in the peer-reviewed paper, which you can read in full below.
Helder, T. A., et al. (2025). The dose-response effects of hydrolysed curcumin on recovery, inflammation, and oxidative stress following exercise-induced muscle damage in males. Physiological Reports, 13(15), e70504. Read the full paper: https://doi.org/10.14814/phy2.70504